Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BON Bon Natural Life	$1.38 +0.0%	$1.38	$1.14 ▼ $73.75	$230K	-0.47	1.77 million shs	47,873 shs
PBLA Panbela Therapeutics	$0.16	$0.18	$0.05 ▼ $0.47	$767K	1.33	16,227 shs	128 shs
PTPI Petros Pharmaceuticals	$0.03 -1.8%	$0.03	$0.02 ▼ $16.25	$857K	1.56	4.98 million shs	260,246 shs
SLRX Salarius Pharmaceuticals	$5.77 +8.5%	$10.94	$4.76 ▼ $108.00	$2.94M	0.45	432,246 shs	36,047 shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BON Bon Natural Life	0.00%	+6.16%	-2.12%	-23.33%	-97.41%
PBLA Panbela Therapeutics	0.00%	0.00%	0.00%	-33.40%	-56.38%
PTPI Petros Pharmaceuticals	0.00%	-10.13%	-8.03%	-29.49%	-99.68%
SLRX Salarius Pharmaceuticals	0.00%	-16.70%	-48.80%	-50.08%	-80.37%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BON Bon Natural Life	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PBLA Panbela Therapeutics	0.3224 of 5 stars	0.0	5.0	0.0	0.0	0.6	0.0	0.0
PTPI Petros Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SLRX Salarius Pharmaceuticals	0.1321 of 5 stars	0.0	2.0	0.0	0.0	2.1	0.0	0.0

Compare Analyst Forecasts

Company	Consensus Rating	Consensus Price Target	% Upside from Current Price
BON Bon Natural Life	N/A	N/A	N/A
PBLA Panbela Therapeutics	N/A	N/A	N/A
PTPI Petros Pharmaceuticals	N/A	N/A	N/A
SLRX Salarius Pharmaceuticals	N/A	N/A	N/A

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BON Bon Natural Life	$23.84M	0.01	$1.77 per share	0.78	$37.78 per share	0.04
PBLA Panbela Therapeutics	N/A	N/A	N/A	N/A	($18.37) per share	N/A
PTPI Petros Pharmaceuticals	$5.11M	0.17	N/A	N/A	$4.04 per share	0.01
SLRX Salarius Pharmaceuticals	N/A	N/A	N/A	N/A	($1.63) per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BON Bon Natural Life	$400K	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
PBLA Panbela Therapeutics	-$25.26M	-$71.13	N/A	∞	N/A	N/A	N/A	-302.61%	11/12/2025 (Estimated)
PTPI Petros Pharmaceuticals	-$8.16M	-$52.91	N/A	∞	N/A	N/A	-78.22%	-23.50%	N/A
SLRX Salarius Pharmaceuticals	-$5.58M	-$43.48	N/A	∞	N/A	N/A	-556.47%	-192.35%	11/12/2025 (Estimated)

Latest BON, SLRX, PTPI, and PBLA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/12/2025	Q2 2025	SLRX Salarius Pharmaceuticals	-$33.00	-$0.45	+$32.55	-$0.45	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BON Bon Natural Life	N/A	N/A	N/A	N/A	N/A
PBLA Panbela Therapeutics	N/A	N/A	N/A	N/A	N/A
PTPI Petros Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SLRX Salarius Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BON Bon Natural Life	0.02	2.42	2.32
PBLA Panbela Therapeutics	N/A	0.26	0.26
PTPI Petros Pharmaceuticals	1.58	0.85	0.74
SLRX Salarius Pharmaceuticals	N/A	0.61	0.61

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BON Bon Natural Life	0.57%
PBLA Panbela Therapeutics	4.37%
PTPI Petros Pharmaceuticals	12.34%
SLRX Salarius Pharmaceuticals	11.88%

Insider Ownership

Company	Insider Ownership
BON Bon Natural Life	26.48%
PBLA Panbela Therapeutics	0.01%
PTPI Petros Pharmaceuticals	12.25%
SLRX Salarius Pharmaceuticals	1.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BON Bon Natural Life	100	167,000	863,000	Not Optionable
PBLA Panbela Therapeutics	6	4.86 million	4.86 million	Not Optionable
PTPI Petros Pharmaceuticals	20	31.16 million	9.93 million	Not Optionable
SLRX Salarius Pharmaceuticals	20	510,000	504,000	Not Optionable

BON, SLRX, PTPI, and PBLA Headlines

Recent News About These Companies

Salarius Pharmaceuticals (NASDAQ:SLRX) Stock Rating Upgraded by Wall Street Zen

August 24 at 2:45 AM | americanbankingnews.com

Salarius Pharmaceuticals Inc (SLRX) - Investing.com

August 20, 2025 | investing.com

Salarius Pharmaceuticals Appoints New Acting CEO

August 19, 2025 | msn.com

Salarius Pharmaceuticals files $50M mixed securities shelf

August 16, 2025 | msn.com

Salarius Pharmaceuticals trading halted, news pending

August 16, 2025 | msn.com

Salarius Pharmaceuticals Announces Reverse Stock Split

August 16, 2025 | msn.com

Salarius Pharmaceuticals, Inc.: Salarius Pharmaceuticals Announces 1-for-15 Reverse Stock Split

August 14, 2025 | finanznachrichten.de

Salarius Pharmaceuticals Announces 1-for-15 Reverse Stock Split

August 14, 2025 | globenewswire.com

Salarius Pharmaceuticals Raises $3.8M Through Stock Sale

July 31, 2025 | msn.com

Salarius Pharmaceuticals Modifies Security Holders’ Rights

July 30, 2025 | msn.com

Salarius Pharmaceuticals stock soars after Nasdaq extends compliance deadline

July 29, 2025 | investing.com

Salarius Pharmaceuticals Granted Additional Extension to Regain Compliance with Nasdaq’s Stockholders’ Equity Standard

July 14, 2025 | finance.yahoo.com

Salarius Pharmaceuticals Granted Additional Extension to Regain Compliance with Nasdaq's Stockholders' Equity Standard

July 14, 2025 | globenewswire.com

Salarius Pharmaceuticals’ Seclidemstat Demonstrates Supporting Role ...

July 11, 2025 | morningstar.comM

Salarius Pharmaceuticals shareholders approve reverse stock split and share issuance

July 10, 2025 | uk.investing.com

Salarius Pharmaceuticals’ Seclidemstat Demonstrates Supporting Role in Inhibiting Validated Oncology Target LSD1 in Two Recently Published Studies

July 10, 2025 | finance.yahoo.com

Salarius Pharmaceuticals' Seclidemstat Demonstrates Supporting Role in Inhibiting Validated Oncology Target LSD1 in Two Recently Published Studies

July 9, 2025 | globenewswire.com

Salarius Granted Nasdaq Extension To Regain Compliance With Listing Standards

June 18, 2025 | nasdaq.com

Salarius Pharmaceuticals faces Nasdaq delisting over rule breaches

April 27, 2025 | investing.com

Salarius Pharmaceuticals announces Langer to join SAB

April 17, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

BON, SLRX, PTPI, and PBLA Company Descriptions

Bon Natural Life NYSE:BON

$1.38 +0.00 (+0.01%)

Closing price 08/22/2025 03:59 PM Eastern

Extended Trading

$1.38 +0.00 (+0.36%)

As of 08/22/2025 07:33 PM Eastern

Bon Natural Life Limited, together with its subsidiaries, engages in the research and development, manufacture, and sale of functional active ingredients extracted from natural herb plants in the People's Republic of China and internationally. It offers personal care ingredients, such as plant extracted fragrance compounds to perfume and fragrance manufacturers; and natural health supplements comprising powder drinks and bioactive food ingredient products used as food additives and nutritional supplements. Its products are used by manufacturer customers in the functional food, personal care, cosmetic, and pharmaceutical industries. The company was founded in 2006 and is based in Xi'an, the People's Republic of China.

Panbela Therapeutics NASDAQ:PBLA

$0.16 0.00 (0.00%)

As of 08/22/2025

Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The company's lead product candidates are Ivospemin (SBP-101), a proprietary polyamine analogue, which has completed Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma; Flynpovi, a combination of eflornithine (CPP-1X) and sulindac which is in Phase III clinical trials; and Eflornithine, an enzyme-activated irreversible inhibitor of the enzyme ornithine decarboxylase, currently under Phase I/II trial. It has a research agreement with the Johns Hopkins University School of Medicine for the development of ivospemin. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.

Petros Pharmaceuticals NASDAQ:PTPI

$0.03 0.00 (-1.79%)

As of 08/22/2025 03:54 PM Eastern

Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics in the United States and internationally. It operates through two segments, Prescription Medications and Medical Devices. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a novel and patented topical formulation candidate for the treatment of acute Peyronie's disease. The company offers men's health products, including vacuum erection devices, penile injections, PreBoost, VenoSeal, and urinary tract infection tests for the treatment of erectile dysfunction. Petros Pharmaceuticals, Inc. is based in New York, New York.

Salarius Pharmaceuticals NASDAQ:SLRX

$5.77 +0.45 (+8.46%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$5.63 -0.14 (-2.44%)

As of 08/22/2025 07:59 PM Eastern

Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds and Cancer Prevention and Research Institute of Texas for product development activities. The company is headquartered in Houston, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time